Trending...
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- The Business Consultant behind The First Black-owned BP
- College Consensus Publishes Aggregate Ranking of the Best Online Master's in Game Design for 2021
DURHAM, N.C., Dec. 1, 2020 /PRNewswire/ -- Dova Pharmaceuticals, Inc., a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), today announced that data on DOPTELET® (avatrombopag), an oral thrombopoietin receptor agonist (TPO-RA) for the treatment of chronic immune thrombocytopenia (ITP), will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting being held as a virtual event, December 5-8, 2020.
"We look forward to presenting data that reinforce the positive efficacy and safety profile of DOPTELET in patients with ITP at the 2020 ASH annual meeting," said Michael Vredenburg, Ph.D., Head of Medical Affairs at Dova. "Specifically, these presentations will provide additional insight into the efficacy and durability of platelet response with DOPTELET treatment in patients suffering from chronic ITP, as well as show new safety and efficacy analyses from the ITP clinical development program."
Poster Presentation Details:
About DOPTELET® (avatrombopag)
DOPTELET® is an oral thrombopoietin (TPO) receptor agonist administered with food. DOPTELET is approved by both the FDA and EMA for the treatment of thrombocytopenia (low platelet counts) in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. In June 2019, DOPTELET was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
More on ncarol.com
Full prescribing information for DOPTELET is available at www.Dova.com.
Important Safety Information
In patients with chronic liver disease, the most common adverse reactions (≥ 3%) were pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.
In patients with chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.
About Dova Pharmaceuticals
Dova Pharmaceuticals is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (Publ) (Sobi) focused on commercializing DOPTELET ® (avatrombopag) for the treatment of thrombocytopenia. DOPTELET is an oral thrombopoietin (TPO) receptor agonist administered with food. More information is available at www.dova.com. For more information about Sobi, visit www.sobi.com.
For more information, please contact:
Lori Rosen, Corporate Communications for Dova
[email protected]
SOURCE Dova Pharmaceuticals
"We look forward to presenting data that reinforce the positive efficacy and safety profile of DOPTELET in patients with ITP at the 2020 ASH annual meeting," said Michael Vredenburg, Ph.D., Head of Medical Affairs at Dova. "Specifically, these presentations will provide additional insight into the efficacy and durability of platelet response with DOPTELET treatment in patients suffering from chronic ITP, as well as show new safety and efficacy analyses from the ITP clinical development program."
Poster Presentation Details:
- Poster #835: Consistent Efficacy Demonstrated by Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment
Session: 311: Disorders of Platelet Number of Function
More on ncarol.com- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- Dollyhood Records Signs Distribution Deal With Sony!
- West Coast Recording Artist, Composer and Actor, Blue Ragg$ Releases New Music & Theatrical Video
- Swaggerty's Receives Highest Possible Grade from BRC Food Safety Auditors for 8th Consecutive Year
Presentation Date: Saturday, December 5, 7:00 am-3:30 pm - Poster #844: Characterization of Thromboembolic Events Occurring During the Avatrombopag Immune Thrombocytopenia (ITP) Clinical Development Program
Session: 311: Disorders of Platelet Number of Function
Presentation Date: Saturday, December 5, 7:00 am-3:30 pm - Poster #2675: Durability of Initial Platelet Count Response in Patients Treated with Avatrombopag for Immune Thrombocytopenia (ITP): Post-hoc Results from a Phase 3 Clinical Study
Session: 311: Disorders of Platelet Number of Function
Presentation Date: Monday, December 7, 7:00 am-3:30 pm
About DOPTELET® (avatrombopag)
DOPTELET® is an oral thrombopoietin (TPO) receptor agonist administered with food. DOPTELET is approved by both the FDA and EMA for the treatment of thrombocytopenia (low platelet counts) in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. In June 2019, DOPTELET was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
More on ncarol.com
- Be an Example, Get the Covid Shot
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- Thiel College names Terry Eddy to Board of Trustees
- Carolina Ballet and LeithCars.com Now Dancing Across Your Television Screen
- Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
Full prescribing information for DOPTELET is available at www.Dova.com.
Important Safety Information
In patients with chronic liver disease, the most common adverse reactions (≥ 3%) were pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.
In patients with chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.
About Dova Pharmaceuticals
Dova Pharmaceuticals is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (Publ) (Sobi) focused on commercializing DOPTELET ® (avatrombopag) for the treatment of thrombocytopenia. DOPTELET is an oral thrombopoietin (TPO) receptor agonist administered with food. More information is available at www.dova.com. For more information about Sobi, visit www.sobi.com.
For more information, please contact:
Lori Rosen, Corporate Communications for Dova
[email protected]
SOURCE Dova Pharmaceuticals
Filed Under: Business
0 Comments
Latest on ncarol.com
- College Consensus Publishes Aggregate Ranking of the Best Online Master's in Social Work for 2021
- North Carolina: Governor Mobilizes NC National Guard for Deployment in Raleigh and Washington, DC
- College Consensus Publishes Aggregate Ranking of the Best Online Master's in Game Design for 2021
- North Carolina: Governor Names Military and Veterans Affairs Secretary
- SHELTER, New Works by Artists Byron Keith Byrd, Stefani Byrd, and Fenix Gallery Collective, January 20–February 24, 2021
- Engage2Excel Releases CXS Recognize 2.1, Focusing on Improving the Employee Experience
- North Carolina Central University Division of Student Affairs Presents Ready to Soar Conference
- Great Business Schools Releases National Rankings of Environmental Sustainability Master's Programs
- AI.Reverie Awarded $950 Million IDIQ Contract for U.S. Air Force Advanced Battle Management System (ABMS)
- Updated ASI Book Helps Association Executives Improve Organizational Performance Now and Post-COVID
- MBK Senior Living Ranks 7th On Fortune Best Workplaces For Aging Services List
- National Board of Certified Counselors, Inc. - Notice of Data Security Event
- North Carolina to Consider Climate Change Solution as Communities Feel Impacts
- Maison Fauna To Release 'Funk Decision' by Foundless
- Fifth Gen Media announces Darlene Pope as Chairman of the Advisory Council
- Maison Fauna to Release Footrocket's What We Learned EP
- Phinge To Launch Netverse, a Rewards-Based Alternative to Apple and Google Using Innovative Proprietary Technology and Patented Mobile Devices
- Kohler Generators Joins Roush Fenway Racing as an Anchor Partner on No. 6
- Spivey Hall Children's Choir Looks To 2021 Through The Lens of Langston Hughes Poetry
- Wohler releases AoIP & Analog options for their iVAM1-1